Age-specific seasonal influenza vaccine effectiveness against different influenza subtypes in the hospitalized population in lithuania during the 2015–2019 influenza seasons
Kuliese, Monika ; Mickiene, Aukse ; Jancoriene, Ligita ; Zablockiene, Birute and Gefenaite, Giedre LU
(2021)
In Vaccines
9(5).
- Abstract
Background: Continuous monitoring of seasonal influenza vaccine effectiveness (SIVE) is needed due to the changing nature of influenza viruses and it supports the decision on the annual update of vaccine composition. Age-specific SIVE was evaluated against different influenza sub-types in the hospitalized population in Lithuania during four influenza seasons. Methods: A test-negative case-control study design was used. SIVE and its 95% confidence intervals (95% CI) were calculated as (1 – odds ratio (OR)) × 100%. Results: Adjusted SIVE in 18–64-year-old individuals against influenza A, A(H1N1)pdm09 and B/Yamagata were 78.0% (95% CI: 1.7; 95.1%), 88.6% (95% CI: −47.4; 99.1%), and 76.8% (95% CI: −109.9; 97.4%), respectively. Adjusted SIVE... (More)
Background: Continuous monitoring of seasonal influenza vaccine effectiveness (SIVE) is needed due to the changing nature of influenza viruses and it supports the decision on the annual update of vaccine composition. Age-specific SIVE was evaluated against different influenza sub-types in the hospitalized population in Lithuania during four influenza seasons. Methods: A test-negative case-control study design was used. SIVE and its 95% confidence intervals (95% CI) were calculated as (1 – odds ratio (OR)) × 100%. Results: Adjusted SIVE in 18–64-year-old individuals against influenza A, A(H1N1)pdm09 and B/Yamagata were 78.0% (95% CI: 1.7; 95.1%), 88.6% (95% CI: −47.4; 99.1%), and 76.8% (95% CI: −109.9; 97.4%), respectively. Adjusted SIVE in individuals aged 65 years and older against influenza A, influenza B, and B/Yamagata were 22.6% (95% CI: −36.5; 56.1%), 75.3% (95% CI: 12.2; 93.1%) and 73.1% (95% CI: 3.2; 92.5%), respectively. Unadjusted SIVE against influenza A(H3N2) among 18–64-year-old patients was 44.8% (95% CI: −171.0; 88.8%) and among those aged 65 years and older was 5.0% (95% CI: −74.5; 48.3%). Conclusions: Point estimates suggest high SIVE against influenza A in 18–64-year-old participants, and against influenza B and B/Yamagata in those 65 years old and older.
(Less)
- author
- Kuliese, Monika
; Mickiene, Aukse
; Jancoriene, Ligita
; Zablockiene, Birute
and Gefenaite, Giedre
LU
- author collaboration
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Hospital surveillance, Influenza, Laboratory-confirmed, Older people, Risk groups, Severe outcomes, Underlying conditions
- in
- Vaccines
- volume
- 9
- issue
- 5
- article number
- 455
- publisher
- MDPI AG
- external identifiers
-
- scopus:85105942302
- pmid:34064455
- ISSN
- 2076-393X
- DOI
- 10.3390/vaccines9050455
- project
- Infectious diseases surveillance, vaccine effectiveness and determinants of acceptance
- language
- English
- LU publication?
- yes
- additional info
- Funding Information: Funding: This study was supported by the Research Council of Lithuania (agreement No. SEN-03/2015), the European Commission Horizon 2020 program (agreement 634446) and by the I-MOVE+ (Influenza Monitoring Vaccines Effectiveness in Europe in Elderly) Network.
- id
- 202bd648-7523-4167-9a2e-9c76b0b71bf7
- date added to LUP
- 2021-06-02 08:36:22
- date last changed
- 2024-07-27 16:22:57
@article{202bd648-7523-4167-9a2e-9c76b0b71bf7,
abstract = {{<p>Background: Continuous monitoring of seasonal influenza vaccine effectiveness (SIVE) is needed due to the changing nature of influenza viruses and it supports the decision on the annual update of vaccine composition. Age-specific SIVE was evaluated against different influenza sub-types in the hospitalized population in Lithuania during four influenza seasons. Methods: A test-negative case-control study design was used. SIVE and its 95% confidence intervals (95% CI) were calculated as (1 – odds ratio (OR)) × 100%. Results: Adjusted SIVE in 18–64-year-old individuals against influenza A, A(H1N1)pdm09 and B/Yamagata were 78.0% (95% CI: 1.7; 95.1%), 88.6% (95% CI: −47.4; 99.1%), and 76.8% (95% CI: −109.9; 97.4%), respectively. Adjusted SIVE in individuals aged 65 years and older against influenza A, influenza B, and B/Yamagata were 22.6% (95% CI: −36.5; 56.1%), 75.3% (95% CI: 12.2; 93.1%) and 73.1% (95% CI: 3.2; 92.5%), respectively. Unadjusted SIVE against influenza A(H3N2) among 18–64-year-old patients was 44.8% (95% CI: −171.0; 88.8%) and among those aged 65 years and older was 5.0% (95% CI: −74.5; 48.3%). Conclusions: Point estimates suggest high SIVE against influenza A in 18–64-year-old participants, and against influenza B and B/Yamagata in those 65 years old and older.</p>}},
author = {{Kuliese, Monika and Mickiene, Aukse and Jancoriene, Ligita and Zablockiene, Birute and Gefenaite, Giedre}},
issn = {{2076-393X}},
keywords = {{Hospital surveillance; Influenza; Laboratory-confirmed; Older people; Risk groups; Severe outcomes; Underlying conditions}},
language = {{eng}},
number = {{5}},
publisher = {{MDPI AG}},
series = {{Vaccines}},
title = {{Age-specific seasonal influenza vaccine effectiveness against different influenza subtypes in the hospitalized population in lithuania during the 2015–2019 influenza seasons}},
url = {{http://dx.doi.org/10.3390/vaccines9050455}},
doi = {{10.3390/vaccines9050455}},
volume = {{9}},
year = {{2021}},
}